Multidisciplinary Head and Neck Tumor Board
Thursday, March 20, 2014
7:15am - 8:00am
Clinical Cancer Center, 3rd floor, Conference Room M
Learning Objectives:
• Implement current evidenced-based management of newly diagnosed and recurrent head and neck cancer
• State the roles of all of the members of the cancer management team
• Assess the physical, radiologic, and pathologic findings that affect treatment choice in head and neck cancer
patients
Name/MR/DOB
B, T
1066XXXX
74 y.o. male
XX/XX/39
M, J
1000XXXX
64 y.o. male
XX/XX/49
H, P
0952XXXX
55 y.o. female
XX/XX/58
Staff
Massey
L, J
0908XXXX
55 y.o. male
XX/XX/59
Campbell
Schultz
Maiman
S, J
0929XXXX
49 y.o male
XX/XX/64
T, R
0937XXXX
80 y.o. female
XX/XX/34
Campbell
B, M
1064XXXX
70 y.o. female
XX/XX/43
Campbell
*** To Be Discussed
OS = Outside
CLTr = Clinical Trials
Massey
Campbell
Campbell
Firat
Wong
Diagnosis/Hx
Recurrent SCC post. pharynx.
Hx: St III, T3N1M0 SCC, p16 +
HP s/p chemoRT (cetuximab)
cmpltd 8/2013.
Oral Cavity SCC
Films/Path
Path: 2-14-14
CT Neck: 2-15-14
PET: 2-6-14
PET pending 3-2114
CT neck 3-6-14
New
Tx N2b M0 (IVA) recurrent
SCC tongue metastatic to the
neck.
HX: 2011: T3N2cM0 (IVA) SCC
R oral tongue s/p surgery,
refused adj tx.
3/2013-recurrentT2 SCC L
ventral tongue s/p WLE
declined RT.
Tx N2c M0 recurrent malignant
chordoma of the spine
Hx: Malignant chordoma spine
2010 s/p resection. Recurred
2/2013 s/p resection f/b RT
cmplted 9/2013.
T2 N0 M0 (II) p16 positive SCC
of the R tonsil
Path: 3-14-14
F/U
TB
3-14-14
Persistent T4a N0 M0 (IVA)
SCC oral cavity
Hx:
2013: T4a (Stage IVA) SCC
mandibular alveolar ridge s/p
RT cmpltd RT 8/27/2013
2008: Vulvar ca s/p surgery/RT.
T4AN0M0 (IVA) SCC R oral
cavity
Hx: 2005 St 2 T1N1 SCC R
oral tongue s/p
hemiglossectomy,bil ND f/b RT.
2008:HBO
2. Stage IIA Inv. lobular
carcinoma R breast, ER +, PR
borderline, HER 2 neg s/p
New
Previously reviewed;
PET: 3-12-14
Neck Chest CT 3-614
MR neck: 3-3-14
CT C-spine: 2-26-14
New
Path: 2-20-14
CT neck 2-7-14
PET: 3-6-14
New
W/U pending
F/U
TB
6/27/13
Path: 3-17-14
Present if path
ready
CT head 3-19-14
CT neck 2-10-14
CT neck angio:
2-20-14
New
Multidisciplinary Head and Neck Tumor Board
J, R
0914XXXX
58 y.o. male
XX/XX/55
Thursday, March 20, 2014
7:15am - 8:00am
Clinical Cancer Center, 3rd floor, Conference Room M
Surgery, Oncotype DX w/ low
recurrence score.
Letrozole 20 mg daily.
Campbell Recurrent T1 N0 M0 (I) SCC of Path: 3-14-15
Present if path
the L FOM
Hx:-pT1N2bM0 (st IVA) SCC of positive
the R lateral tongue resected in
2003, f/b RT cmpltd in 9/2003. -4/2004-T1N0M0,st.I,
contralateral (L) lateral tongue
was excised
-New primary T1N0M0 (stage I)
SCC L FOM s/p WLE 2/2013.
F/U
TB
2-4-13
**During the discussions of the treatment plans for the above listed patients, evidence based guidelines including, but not
limited to, NCCN were utilized. H&N Cancer patients that will be having radiation, + or – chemo or have wt. loss or
swallowing problems, or both are all offered nutritional consults pre-treatment and are followed thru treatment. In the
interest of space, this is not listed for each individual patient.
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Live Activity for a maximum of 1 AMA PRA Category 1 Credit(s)
™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME® standard for Commercial Support Number 6, all in control of content disclosed any
relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and
resolved: Dr. Michelle Michel with Amirsys, Inc as Author and Consultant; Dr. Becky Massey with Olympus as Consultant.
In accordance with the ACCME® standard for Commercial Support Number 6, all in control of content disclosed any
relevant financial relationships. The following in control of content had no relevant financial relationships to disclose: Dr.
Bruce Campbell and Kathy Myers, BSN.
*** To Be Discussed
OS = Outside
CLTr = Clinical Trials